Brief: INmune Bio Receives EMA Authorization In France And Spain For Phase II Clinical Trial Of XPro For Early Alzheimer’s Disease
27/11/2023 14:36
Nov 27 (Reuters) - INmune Bio Inc INMB.O :
* INMUNE BIO RECEIVES EMA’S AUTHORIZATION IN FRANCE AND
SPAIN FOR
PHASE II CLINICAL TRIAL OF XPRO™ FOR EARLY ALZHEIMER’S DISEASE
Source text for Eikon: ID:nGNXXCGf4
Further company coverage: INMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview